Merck’s enlicitide has become the first oral PCSK9 inhibitor approved by the FDA, producing placebo-adjusted LDL reductions of 56% to 59% at 24 weeks in pivotal trials. After a decade of injectable-only options and persistent uptake problems, the cardiovascular drug market has a genuinely new option. Whether it delivers what the injectables never quite could depends on what happens next.

Heart disease remains the leading cause of death worldwide. Elevated LDL cholesterol is one of its most established and modifiable risk factors. Statins, the standard first-line treatment, are among the most prescribed medicines in history and have saved millions of lives. But a significant proportion of high-risk patients cannot reach their LDL targets on statins alone, either because their cholesterol is too high to start with, because they carry a genetic condition called familial hypercholesterolaemia, or because they cannot tolerate statins at the doses needed.

For that population, a more powerful class of drugs called PCSK9 inhibitors has been available since 2015. They are highly effective. They are also, until this week, only available as injections. That has changed.

On 16 July, the FDA approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9, as an adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolaemia, including those with heterozygous familial hypercholesterolaemia. The approval marks the first time the PCSK9 pathway specifically has been accessible through a daily pill rather than a subcutaneous injection. Other lipid-lowering medicines are available orally, and inclisiran, a newer injectable targeting the same pathway, requires only twice-yearly dosing, but no oral PCSK9 inhibitor has previously been approved.

How PCSK9 Inhibition Works

PCSK9 is a protein produced naturally by the liver that degrades LDL receptors, the structures on liver cell surfaces that clear LDL cholesterol from the bloodstream. The more LDL receptors available, the more cholesterol the liver can remove from circulation. By inhibiting PCSK9, these drugs preserve LDL receptor numbers, allowing the liver to clear far more cholesterol than it otherwise would.

Enlicitide uses the same mechanism as injectable monoclonal antibodies like evolocumab and alirocumab, but is delivered as a 20-milligram tablet rather than a subcutaneous injection. The innovation that makes oral delivery possible is the drug’s molecular structure. Enlicitide is a macrocyclic peptide, a small, looped amino acid chain that combines properties of both biologics and small-molecule drugs. Standard peptide drugs are typically broken down in the digestive system before they can be absorbed. Macrocyclic peptides are more structurally rigid and, combined with formulation strategies to optimise permeability, are better able to survive transit through the gut and reach the bloodstream in clinically useful concentrations.

What the Trial Data Show

The approval rests on results from two Phase 3 trials, CORALreef Lipids and CORALreef HeFH. At week 24 in both trials, Lipfendra produced placebo-adjusted mean LDL reductions of 56% and 59% respectively.

For context, the established injectable PCSK9 inhibitors produce broadly similar reductions in trials: evolocumab has been reported to reduce LDL by approximately 60% and alirocumab by roughly 45% to 60% depending on dose and patient population. No head-to-head trials comparing enlicitide directly with either injectable have been conducted, which means cross-trial comparisons carry inherent limitations. What can be said is that the magnitude of LDL reduction seen with Lipfendra in its pivotal trials falls within the range observed with the existing injectable class.

CORALreef Lipids randomly assigned 2,904 patients with hypercholesterolaemia, with and without familial hypercholesterolaemia, who had a history of a major atherosclerotic cardiovascular disease event or elevated risk of a first event, in a two-to-one ratio to enlicitide 20 milligrams once daily or placebo for 52 weeks. All participants required additional LDL reduction despite stable therapy with moderate or high-intensity statins, and patients already taking PCSK9 inhibitors were excluded. CORALreef HeFH applied the same design in 303 patients with familial hypercholesterolaemia diagnosed by clinical criteria or genotyping.

Beyond LDL, both trials showed reductions in other atherogenic lipoproteins associated with cardiovascular disease risk, including a 54% mean reduction in non-HDL cholesterol in CORALreef Lipids.

The safety profile was broadly reassuring. The most common adverse reactions occurring more frequently with enlicitide than placebo in the HeFH trial were diarrhoea, at 7% versus 2%, and dizziness, at 9% versus 4%. In both trials, similar proportions of enlicitide-treated and placebo-treated patients discontinued treatment because of an adverse reaction.

One critical caveat applies to the efficacy picture: at the time of approval, enlicitide has not demonstrated a reduction in cardiovascular events such as heart attacks or strokes. Merck has noted that an ongoing clinical trial, CORALreef Outcomes, is evaluating the effect of enlicitide on cardiovascular outcomes. That trial is expected to report around 2029. The injectable PCSK9 inhibitors received initial approval on the basis of LDL reduction before their landmark outcomes trials were completed, and those trials subsequently confirmed cardiovascular benefit. Whether enlicitide follows the same path remains to be established.

Why the Injectables Never Fulfilled Their Potential

The history of injectable PCSK9 inhibitors is a useful backdrop for understanding what an oral alternative might achieve. Since reaching the market a decade ago, PCSK9 inhibitors have not lived up to their initial expectations. Whilst drugs such as Amgen’s Repatha and Regeneron and Sanofi’s Praluent have proven more effective than statins at reducing LDL cholesterol, their uptake was initially blunted by price and access limitations.

The injection barrier has been a genuine and documented obstacle. Patients who are needle-averse, who lack support for self-administration, or who find the logistics of refrigerated injectable medicines burdensome have been underserved by existing options. Prescribers have also faced prior authorisation hurdles and formulary restrictions that have limited access in both the US and European markets, particularly in the class’s early years.

Macrocyclic peptide technology enables oral delivery, potentially expanding PCSK9 pathway use beyond injectable biologics and addressing adherence and access barriers in long-term lipid management. That is the central clinical argument for Lipfendra: not that it has been proven superior to the injectables, but that it may reach patients who have not previously been willing or able to use them.

Commercial Prospects

Financial analysts have said the drug has the potential to generate over $2 billion in annual sales after a few years on the market. That projection is inherently speculative at this stage, but reflects the size of the addressable patient population and the historical gap between clinical need and actual uptake of the injectable PCSK9 class.

The drug must be taken on an empty stomach in the morning with water, black coffee or plain tea, a dosing requirement that may affect adherence in some patients and is worth monitoring as post-approval data accumulate. Pricing has not yet been announced at the time of writing, and the degree to which payers and formulary managers in the US and other markets embrace oral PCSK9 inhibition will substantially determine how widely the medicine reaches patients.

A Platform With Broader Implications

The approval carries significance beyond cardiovascular medicine. Macrocyclic peptides are having a moment, according to a recent analysis by Chemical and Engineering News and CAS, a division of the American Chemical Society. Enlicitide’s approval demonstrates that the platform can deliver a complex molecule orally with LDL-lowering magnitude comparable to injectable biologics in clinical trials, a meaningful result for drug developers working on other targets where oral delivery has historically been impossible. Long-term equivalence with injectables in terms of cardiovascular outcomes remains to be established.

For patients managing chronic cardiovascular risk, the practical message is straightforward. An oral once-daily pill producing LDL reductions in the range seen with injectable PCSK9 inhibitors, with a broadly tolerable safety profile, is now approved. Whether it fulfils the potential that the injectable class never quite reached will depend on pricing, access decisions and the outcomes data still to come.

Primary sources: US Food and Drug Administration press announcement 16 July 2026; Merck news release 16 July 2026; American Journal of Managed Care; Pharmacy Times; Fierce Pharma; Chemical and Engineering News.